[在个性化和标准化剂量中比较gemcitabine的生产成本]
Mélanie Closset1, Louise Lombet2, Justine Hubert3
1Laboratoire de biologie clinique, avenue Thérasse 1, 5530 Yvoir, Belgique; Drug Stability Research Group, CHU UCL Namur, avenue Thérasse 1, 5530 Yvoir, Belgique; URL7365 - Groupe de recherche sur les formes injectables et les technologies associées (GRITA), CHU de Lille, université de Lille, 59000 Lille, France.
Bulletin du cancer
|April 1, 2025
概括
与个性化制备相比,用于凝胺化疗生产的剂量组合显著降低了7%的成本. 这种批量生产方法为标准化癌症药物制造提供了更经济的方法.
科学领域:
- 在瘤学瘤学.
- 制药生产 制药生产
- 卫生经济学 卫生经济学
背景情况:
- 化疗剂量通常取决于患者的身体表面积,需要个性化准备.
- 剂量分组提供了一个替代方案,通过分批生产临床定义的固定的剂量,允许 ±5%的标准偏差.
- 本研究评估了这两种生产方法对宝石的经济影响.
研究的目的:
- 为了比较个性化与批量生产的gemcitabine的生产成本.
- 为了确定集中化疗单元中剂量组合的经济可行性.
主要方法:
- 采用了成本最小化分析.
- 在一年内确定适合标准化 (±5%偏差) 的gemcitabine制剂.
- 对比个性化和大规模生产的直接和间接成本.
主要成果:
- 大约69.8%的吉姆西塔制剂有资格进行标准化.
- 标准化剂量包括1500mg,1600mg,1800mg,2000mg和2200mg (±5%). 这些剂量包括:
- 剂量减量导致一年内生产成本降低7%.
结论:
- 使用剂量组合的批量生产比个性化凝制剂更具成本效益.
- 这些发现表明,通过将剂量组合扩展到其他抗癌剂,可以节省潜在的成本.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Bioequivalence: Overview
892
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
892


